Fleury SA (FLRY3)

Currency in BRL
12.82
+0.05(+0.39%)
Closed·
FLRY3 Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
FLRY3 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.6912.94
52 wk Range
10.6216.60
Key Statistics
Bid/Ask
12.82 / 12.95
Prev. Close
12.77
Open
12.88
Day's Range
12.69-12.94
52 wk Range
10.62-16.6
Volume
3.83M
Average Volume (3m)
2.77M
1-Year Change
-15.19%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FLRY3 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.86
Upside
+15.94%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Fleury SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

FLEURY ON Company Profile

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and imaging tests, genomics, health management and platform, diagnostic information, check-up and reference laboratory, clinic day, infusion center, orthopedics and ophthalmology, dental imaging tests, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including scheduling and performing teleconsultations, and face-to-face consultations, as well as scheduling and accessing diagnostic test results, electronic medical record, and self-manage health issues. It operates customer service units and hospital-based units under the Fleury, Felippe Mattoso, Labs a+, Diagnoson a+, Papaiz, Serdil, LAFE, Instituto de Radiologia de Natal, Centro de Patologia Clínica, Diagmax, Santécorp, a+SP, CIP, Saha, Moacir Cunha, Vita, e Campana, Methodos, Pretti, Bioclinico, a+PE, Marcelo Magalhaes, Inlab, Weinmann, a+, a+BA, IRN, CPC, and a+PI brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.

Employees
27500
Market
Brazil

Compare FLRY3 to Peers and Sector

Metrics to compare
FLRY3
Peers
Sector
Relationship
P/E Ratio
11.1x16.3x−0.5x
PEG Ratio
0.520.240.00
Price/Book
1.3x1.1x2.6x
Price / LTM Sales
0.9x1.0x3.2x
Upside (Analyst Target)
13.5%20.5%45.4%
Fair Value Upside
Unlock20.6%6.7%Unlock

Analyst Ratings

4 Buy
5 Hold
2 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 14.86
(+15.94% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.15%
Dividend Yield
3.64%
Industry Median 1.98%
Annualised payout
0.47
Paid unevenly
5-Years Growth
+2.67%
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.329 / 0.34
Revenue / Forecast
2.02B / 2.03B
EPS Revisions
Last 90 days

FLRY3 Income Statement

FAQ

What Is the FLEURY ON (FLRY3) Stock Price Today?

The FLEURY ON stock price today is 12.82.

What Stock Exchange Does FLEURY ON Trade On?

FLEURY ON is listed and trades on the B3 Stock Exchange stock exchange.

What Is the Stock Symbol for FLEURY ON?

The stock symbol for FLEURY ON is "FLRY3."

Does FLEURY ON Pay Dividends? What’s The Current Dividend Yield?

The FLEURY ON dividend yield is 3.64%.

What Is the FLEURY ON Market Cap?

As of today, FLEURY ON market cap is 6.99B.

What Is FLEURY ON's Earnings Per Share (TTM)?

The FLEURY ON EPS (TTM) is 1.15.

When Is the Next FLEURY ON Earnings Date?

FLEURY ON will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is FLRY3 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has FLEURY ON Stock Split?

FLEURY ON has split 2 times.

How Many Employees Does FLEURY ON Have?

FLEURY ON has 27500 employees.

What is the current trading status of FLEURY ON (FLRY3)?

As of 17 Jul 2025, FLEURY ON (FLRY3) is trading at a price of 12.82, with a previous close of 12.77. The stock has fluctuated within a day range of 12.69 to 12.94, while its 52-week range spans from 10.62 to 16.60.

What Is FLEURY ON (FLRY3) Price Target According to Analysts?

The average 12-month price target for FLEURY ON is BRL14.86364, with a high estimate of BRL19.5 and a low estimate of BRL11.5. 4 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +15.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.